Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
| AMLX Etf | USD 3.78 0.06 1.56% |
Slightly above 62% of Amylyx Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Amylyx Pharmaceuticals etf suggests that many investors are alarmed at this time. Amylyx Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Amylyx Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Amylyx |
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Read at businesswire.com
 |
Amylyx Pharmaceuticals Fundamental Analysis
We analyze Amylyx Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amylyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amylyx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Amylyx Pharmaceuticals is currently under evaluation in cash per share as compared to similar ETFs. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Amylyx Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Amylyx Pharmaceuticals etf to make a market-neutral strategy. Peer analysis of Amylyx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Amylyx Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Amylyx Pharmaceuticals Related Equities
| ABOS | Acumen Pharmaceuticals | 7.56 | ||||
| PDSB | PDS Biotechnology | 6.13 | ||||
| INZY | Inozyme Pharma | 2.89 | ||||
| XFOR | X4 Pharmaceuticals | 2.74 | ||||
| TERN | Terns Pharmaceuticals | 2.35 | ||||
| DAWN | Day One | 0.32 | ||||
| MREO | Mereo BioPharma | 0.57 | ||||
| HOOK | Hookipa Pharma | 2.99 |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.